Rongchang Biotech, a victory for high-efficiency innovative solutions

Ask AI · How is Rongchang Bio’s high-efficiency innovation changing the competitive landscape of the industry?

In 2025, Rongchang Bio’s performance is more than impressive: the company’s operating revenue rose to 3.251 billion yuan, up 89.36% year over year; the attributable net profit reached 710 million yuan. Both of these figures are the highest records since the company was founded.

Looking across all major core metrics in 2025, what this China-leading innovative drug company has demonstrated is a rare kind of innovation efficiency: it can, within a relatively short cycle, move R&D results through to commercialization, get marketed products into the national reimbursement system and hospitals, and then drive the core molecules to secure overseas collaborations.

For innovative drug companies, efficiency itself is the barrier that determines the ceiling. Competition in this industry has never been just a race between molecules; it is also a contest of organizational coordination capability.

Only by converting source innovation into cash flow that supports further innovation efficiently—using a shorter time frame and lower trial-and-error costs—can a company secure a first-mover advantage in industry competition.

From this perspective, Rongchang Bio’s explosive growth in its 2025 financial data is only “the tip of the iceberg.” Most valuable is that across multiple core areas such as commercialization, BD transactions, and pipeline R&D, the company is gradually forming a positive closed loop driven by innovation efficiency and oriented toward the value of results.

1、Commercialization efficiency that is steadily improving

Rongchang Bio’s profitability in 2025 is fundamentally different from the company’s prior profitable period in 2021.

In 2021, the company relied more on one-off BD upfront payment income to achieve profitability, but in 2025 the revenue structure has been completely rewritten: full-year revenue reached 3.251 billion yuan, of which domestic sales revenue from marketed innovative drugs was 2.271 billion yuan, maintaining a trend of rapid growth for four consecutive years; commercialization sales has become the core engine supporting the company’s profitability.

The difference between these two profitability periods is undoubtedly crucial to a company’s development.

BD upfront payment income is, in essence, episodic—value being realized under an event-driven model, rather than a stable reflection of a company’s everyday operating capabilities.

In contrast, innovative drug sales revenue is continuous and accumulative. Behind it is a fully matured set of operating systems and a stable creation of cash flow. This is a clear marker that the company has entered an entirely new value stage.

From the上市 of its first product in 2021 to surpassing 2.2 billion yuan in domestic sales—this continuously transforming commercialization process took Rongchang Bio only a little over 4 years to complete.

The China innovative drug market has never been a market that naturally scales up based on approval documents alone. Between getting a product approved and forming large-scale sales, there is a series of hurdles: reimbursement inclusion, hospital formulary inclusion, educating patients and clinicians, establishing prescribing habits, channel cash collection, and more.

Rongchang Bio’s ability to cross these layered real-world obstacles within a relatively short cycle indicates that the company’s commercialization system build-out speed, execution strength, and organizational coordination efficiency are all at an industry-leading level.

As of December 31, 2025, Rongchang Bio’s own autoimmune commercialization team consisted of about 900 people, and it has completed more than 1,200 hospitals’ drug formulary inclusion; the oncology commercialization team consisted of about 500 people, and it has completed more than 1,050 hospitals’ drug formulary inclusion.

Taken together, the commercialization teams corresponding to these two product lines have reached about 1,400 people, with the total number of included hospitals exceeding 2,000. Rongchang Bio has successfully built a dual-engine commercialization network in the domestic market that spans two major core tracks—autoimmune diseases and solid tumors—and has begun to show a scale-driven effect.

While this commercialization system is completing large-scale coverage, it is also revealing an even more important efficiency advantage.

In 2025, the sales volume of Tithercept (RC18) was 2.255 million vials, up 47.92% year over year; the sales volume of Vedicituximab (RC48) was 301,900 vials, up 27.31% year over year. While core products were significantly ramping up, there was no sign of cost inflation. Instead, the sales expense ratio decreased by 6.9% year over year.

This is a very encouraging fundamental trend.

When it comes to commercialization of innovative drugs, the biggest fear is not how large the initial investment is, but that the investment cannot be turned into foundational capabilities that can be reused over the long term. Rongchang Bio has clearly managed to avoid the biggest trap in this commercialization process.

The decrease in sales expense ratio alongside higher sales in 2025 indicates that Rongchang Bio’s commercialization system has already passed the most expensive phase of upfront investment and is now entering a harvest period where efficiency is continuously optimized and marginal output keeps improving. Commercialization capability is being internalized as one of the company’s competitive moats.

With additional indications and product approvals, this increasingly mature commercialization system will become Rongchang Bio’s long-term moat.

2、Explosive BD efficiency

In addition to the historical breakthrough in innovative drug sales revenue, the 2025 performance surge also owes a great deal to outbound BD transactions.

From 2025 through January 2026, Rongchang completed three consecutive outbound BD authorizations:

First, RC18 (Tithercept) was licensed to Vor Bio. The transaction terms include a $45.0 million upfront payment, $80.0 million in share warrants, up to $4.105 billion in milestones, and single-digit to low double-digit percentage sales royalties;

Second, RC28-E was licensed to Santen China. Rights cover Greater China and multiple Asian markets. Rongchang received a RMB 250 million upfront payment, up to RMB 520 million in development and registration milestones, up to RMB 525 million in sales milestones, and tiered royalties;

Third, RC148 was licensed to AbbVie. Rongchang retains rights in Greater China. The agreement includes a $650 million upfront payment, up to $4.95 billion in milestones, and double-digit tiered sales royalties.

Completing three outbound BD transactions in a short time is a high-difficulty task—especially even in today’s environment where BD deals in China’s innovative drug industry are highly active.

While the trigger for a single deal may involve some happenstance, completing three transactions in succession surely reflects deeper underlying inevitability factors. The company’s platformized innovation and organizational BD capabilities—from molecule discovery, to clinical advancement, to deal design—have matured and are operating smoothly.

Beyond landing efficiently, the most noteworthy aspect of these three BD deals from Rongchang Bio is that deal quality is maintained at an extremely high standard: the company successfully designed highly differentiated collaboration plans based on pipeline characteristics across different maturity levels, different tracks, and different clinical value. It then licensed each of the three pipelines to the most suitable partners using the most appropriate approaches.

In the innovative drug industry, asset value is never static. The final outcome depends not only on the molecule itself, but also on who develops it, which markets it advances in, and what kind of clinical strategy and deal structure are used to realize that value. Rongchang Bio’s BD strategy clearly takes this into account and breaks down BD licensing into a process that is manageable, predictable, and replicable.

RC18 represents expansion opportunities in the global autoimmune disease track. What’s needed is a partner with a high strategic focus and willingness to stake “all their assets” on it. A partner like Vor Bio, which reshapes the company’s strategic direction with RC18 as the key pivot, is practically tailored for RC18.

RC28-E is a specialized ophthalmology asset. Its value realization depends heavily on the ophthalmology physician network, regional formulary access, and specialized commercialization capability. Santen has near-unique advantages in this track.

RC148 is a global strategic asset with potential to rewrite the competitive landscape. It requires a top multinational pharma like AbbVie to run the program—so it can support deep development and rapid advancement in the highly competitive hot track of PD-1/VEGF. At the same time, AbbVie has clearly stated it will strongly推进 RC148 together with its other oncology pipelines in development, which will further amplify RC148’s commercial value.

All three transactions point to a principle like this: the hallmark of high-efficiency BD is not merely raising upfront payments; it places more emphasis on improving the probability of realizing long-term value across the entire deal.

In other words, Rongchang Bio’s BD is never a simple “the highest price wins” strategy. It is about choosing the collaboration partner most likely to keep growing an in-development pipeline asset. This directly affects the probability of milestone realization later on and the sales royalty ceiling.

In this process, what Rongchang Bio demonstrates is BD transaction capability that is highly mature across multiple dimensions, including partner selection, pipeline asset stratification, and deal-structure design.

3、Consistently excellent R&D efficiency

Whether it is the sustained ramp-up on the sales side or the concentrated BD explosion on the transaction side, what fundamentally determines the direction of these back-end segments is R&D efficiency and quality.

In 2025, Rongchang Bio’s R&D system shows an operational state with more features of industry maturity: multiple pipelines are advanced in parallel; multiple key milestones are achieved one after another; and innovation outputs are starting to be released in a more concentrated way with higher efficiency and higher quality.

First, the two already marketed core products—Tithercept (RC18) and Vedicituximab (RC48)—continue to expand their boundaries.

Tithercept has already obtained approval licenses for three indications in China: systemic lupus erythematosus (SLE), myasthenia gravis (MG), and rheumatoid arthritis (RA). Among them, in May 2025 the MG indication was approved and launched; by the end of 2025 the MG indication was included in the National Reimbursement Drug List; and the SLE indication has successfully been renewed again.

In addition, Tithercept has already successfully reached endpoints in its Phase III studies in IgA nephropathy and Sjögren’s syndrome, and has submitted applications for marketing authorization.

In 2026, the approved indications for Tithercept are expected to increase to five, further boosting commercialization imagination space.

However, this is far from the full set of expectations. At present, the Phase III clinical studies for Tithercept in ocular myasthenia gravis and in connective tissue disease-associated interstitial lung disease have been initiated. The company is also planning additional Phase III programs such as autoimmune encephalitis, pediatric SLE, pediatric IgA nephropathy, and membranous nephropathy.

For this broad-spectrum autoimmune disease therapy, a commercialization ceiling is still not visible.

In 2025, progress for Vedicituximab has also been significant, pushing toward a larger indication space and a more front-line treatment position.

In 2025, the biggest progress for Vedicituximab was in first-line urothelial carcinoma (UC) treatment: the Phase III study RC48-C016 evaluating the combination of Vedicituximab plus Terepulimab in first-line UC achieved both the two major endpoints—PFS and OS—in the interim analysis. The related study was successfully published in The New England Journal of Medicine, and the marketing authorization application for this indication was submitted in July 2025.

If the above indications are approved, it is not only expected to reshape the landscape of first-line UC treatment, but also to add fresh momentum to the continued ramp-up of Vedicituximab commercialization.

In addition, for the two indications of first-line treatment of locally advanced or metastatic HER2-expressing gastric cancer and neoadjuvant treatment of HER2-expressing muscle-invasive bladder cancer (MIBC), the combination therapy of Vedicituximab and Terepulimab also read out new positive data in 2025. The development prospects are highly值得期待.

Among the in-development pipelines not yet marketed, RC148 is the variable most worth watching in 2025.

The annual report shows that this targeted PD-1/VEGF bispecific antibody received Breakthrough Therapy Drug designation from the Center for Drug Evaluation of the National Medical Products Administration in August 2025 for the treatment of non-small cell lung cancer.

As of the end of the reporting period, RC148 had 6 clinical trials conducted or approved domestically, including several major indications such as first-line treatment of NSCLC.

More importantly, Phase III studies for RC148 combined with chemotherapy in second-line treatment of NSCLC under IND, and a Phase II study for RC148 combined with chemotherapy across multiple solid tumors under IND, both received approval from the U.S. FDA.

This means that in 2025, RC148 has officially become a mid-to-late-stage asset entering global pivotal registration clinical trials.

The pipeline build-out for earlier-stage programs has also produced results: in July 2025, RC278, a novel CDCP1-targeting ADC, received CDE approval to initiate Phase I/II clinical trials; and RC288, a bispecific ADC targeting PSMA/B7H3, has already entered the IND preparation stage.

In 2025, another significant change on Rongchang Bio’s R&D side is the continuous expansion and upgrading of the underlying technology platforms.

Currently, the company has formed a complete set of core technology systems, including an antibody fusion protein platform, an ADC platform, a bispecific antibody platform, a bispecific antibody ADC platform, and a PR-ADC platform. Among them, for the ADC platform, the company is exploring next-generation toxins, linkers, and site-specific bridging technologies, with the goal of building the next-generation ADC with improved safety and efficacy.

In the long run, the R&D platform determines the efficiency with which the company produces next-generation core assets. Rongchang Bio’s iteration and upgrade of this core R&D infrastructure in 2025 will undoubtedly further strengthen the company’s competitive moat and improve its room for future development.

While R&D outputs are showing strong achievements, Rongchang Bio’s R&D costs have not risen along with it; instead, they have declined: the company’s R&D expense in 2025 was 1.22 billion yuan, down 20.85% compared with the prior year.

In the annual report, the company provides two explanations: first, after some pipelines completed BD, the later-stage R&D expenses are borne by its partners; second, the company has optimized its own R&D pipelines proactively.

Rather than blindly spending more money to pile on more projects, but using a clearer trade-off strategy with clinical value and market value as the core guidance to achieve higher-quality R&D outputs—this reflects Rongchang Bio’s continued maturation at the strategic level.

The annual report also shows that the number of R&D personnel decreased from 926 to 864, and total compensation for R&D staff also declined significantly. However, the three major R&D centers are still operating efficiently, and the core platforms continue to be improved. This means the company has not relaxed its R&D capability building; it is instead compressing ineffective expenditures as much as possible and improving unit output efficiency.

For China’s innovative drug companies, the significance of this change is very重大. Because the industry’s true watershed has never been about who spends more money, but about who spends that money with higher efficiency. Behind Rongchang Bio’s decline in R&D expenses in 2025, what is truly worth paying attention to is this significant increase in transformation efficiency.

4、Conclusion

In the context of deep development in the innovative drug industry, innovation is indeed the bottom line for biotech and pharmaceutical companies to survive. But the core variable that truly determines where a company’s long-term development will go—and who ultimately wins or loses—has quietly shifted to a higher-efficiency innovation transformation rate.

Revisiting Rongchang Bio’s 2025: whether it is the historic breakthrough in commercialization sales, the high-frequency monetization of BD transactions, or the hard-core advancement in clinical pipeline R&D—at bottom, all of them are an industrialized, extreme interpretation of the words “innovation efficiency.”

This leap in efficiency, built on systematic underlying capabilities, is transforming Rongchang Bio from a locally leading innovative drug company into a global participant in the international innovative drug market with real competitive strength.

Author statement: Health and medical sharing is for reference only